|
Home | Medical-Newswire.Com:
|
(EMAILWIRE.COM, November 03, 2009 ) November 3, 2009, New York, NY - Keros Client, MabCure Inc. (OTCBB: MBCI), a biotech company that has developed a series of highly specific monoclonal antibodies (Mabs) to combat various types of cancers, is highlighted in the October issue of GEN (Genetic Engineering & Biotechnology News). The article, written by Keith A. Markey, titled "Firms Seek to Prove Cancer Stem Cell Hypothesis," describes MabCure as a company involved in developing immunotherapy against molecules on cancer stem cell surfaces that differ in quantity or quality from those on normal cells.
"MabCure has a program...that targets less-antigenic cell markers, based on an assumption that they have escaped immune detection," writes Markey. "The company has prepared antibodies against ovarian, colorectal, and prostate cancers, as well as melanoma, for diagnostic tests, and later for therapeutic agents."
GEN article can be accessed at: http://www.genengnews.com/articles/chitem.aspx?aid=3066
MabCure is highlighted as well in a new industry report, titled "Targeting Cancer Stem Cells," also written by Keith A. Markey and released by Griffin Securities. In the report, MabCure is described as developing antibodies against specific malignancies and as operating on the belief that that the optimal antigens for therapeutic purposes are not those that are easily recognized by the immune system, but rather are the least antigenic. The report goes on to state: "[MabCure] has developed proprietary techniques for stabilizing the surfaces of cells to preserve subtle features of even weak antigens, and it has optimized its technique for generating monoclonal antibodies. Thus far, [MabCure] has prepared antibodies against ovarian and prostate cancers, as well as melanoma." The Griffin report can be accessed at http://www.griffinsecurities.com/pdf/Industry_Reports/Griffin_Industry_Report_-_Targeting_Cancer_Stem_Cells_14Sep09.pdf.
About GEN
Genetic Engineering & Biotechnology News (GEN), the only high-frequency publication dedicated to biotech news, from bench to business, was introduced in 1981 as the first biotechnology trade publication. Now in its twenty-seventh year, GEN retains its position as the most widely read biotechnology publication around the globe.
Published twenty-one times a year, GEN's unique news and technology content focus includes the entire bioproduct life cycle from early-stage R&D to applied research and bioprocess through to commercialization. GEN is the only publication that provides the full range of the biotechnology market coverage in areas such as omics, drug and biomarker discovery, bioprocessing, clinical research, molecular diagnostics, and biobusiness. For more information, visit http://www.genengnews.com.
About MabCure Inc.
MabCure is a biotechnology company whose vision is to change the perception of cancer as being a largely incurable disease. MabCure owns proprietary technology for the creation of unique and highly specific monoclonal antibodies (MAbs), which will be developed as diagnostic tools, imaging agents, and drugs to treat lethal cancers. MabCure initial goal is to develop its novel MAbs as diagnostic tools for the detection of Ovarian and Prostate cancers at an early stage, when these diseases are still localized and highly curable. For further information visit the Company's website www.mabcure.com.
Disclosure: All material herein was prepared by Keros Capital Inc. (Keros) based upon information believed to be reliable. The information contained herein is not guaranteed by Keros to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Keros is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://www.keroscapital.com or mentioned herein. Keros has been compensated seven thousand five hundred dollars for this advertising effort. Keros may receive additional compensation for future advertisements. Keros affiliates, officers, directors and employees may own shares and may buy and sell additional shares of the company mentioned herein and may profit in the event those shares rise in value. Keros will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market. Copyright 2007 by Keros Capital. All rights reserved. This publication or part thereof may not be duplicated or reprinted without the written permission of the Publisher. Facsimile including photocopy(s) is strictly forbidden, except for facsimile correspondence between Keros Capital. If this publication contravenes any securities laws and/or regulations, the securities regulations of the country will prevail. In this event, this publication must be discarded immediately.
MabCure Inc.
Jim Mav
908-464-1747
jimmav@keroscapital.com 
Source: EmailWire.com
|
|
|
|
